Categories
Upcoming Events

After careful consideration and comprehensive evaluation of currently available information related to the novel coronavirus (COVID-19) outbreak, Macrophage Pharma has made the decision not to travel for the foreseeable future to upcoming events & conferences. We remain focused on supporting the wellbeing and safety of our staff. Thank you and best wishes through this period.

Categories
Our News

Macrophage Pharma Expands Executive Team with Chief Scientific Officer and Chief Technology Officer

Key hires enhance management for next development phase

09 January 2020, Windsor, UK: Macrophage Pharma Limited (“MPL”), a biotech company focused on the discovery and development of next-generation immunomodulatory small molecules inducing transcriptional reprogramming of macrophage function to combat cancer and other diseases, announced today that it has appointed Venkat Reddy PhD as Chief Scientific Officer (CSO) and David Moffat PhD, MPL co-founder and former director of chemistry, as Chief Technology Officer (CTO).

Commenting on the appointments, Dr Søren Bregenholt, MPL Chief Executive Officer said: “On behalf of the executive team I am pleased to welcome Venkat as CSO and David in his new role as CTO as the Company progresses to its next stage of development. Venkat’s deep understanding of pharmaceutical R&D, extensive experience in drug discovery, translational research and early development combined with David’s profound knowledge of our foundation Esterase Sensitive MotifTM (ESMTM) technology, which he co-invented, and drug discovery, will continue to be invaluable as we advance towards clinical trials this year, diversify the technology platform and build out the pipeline to address multiple indications.”

Dr. Venkat Reddy, CSO of Macrophage Pharma, commented: “I am excited to join Macrophage Pharma as CSO and look forward to advancing and expanding the Company’s unique technology platform, exemplified by a drug candidate on track to enter clinical trials. This novel platform allows us to manipulate macrophage and other immune cell functions with the potential to impact areas of unmet need. The differentiation of MPL’s foundation technology from contemporary immune-oncology approaches offers an effective route to functional manipulation of macrophages in the tumour microenvironment by inhibiting local immunosuppression and leading to more effective anti-tumour immune responses. I look forward to working with the management and board to unlock the full therapeutic potential of the ESMTM platform to deliver first-in-class therapeutics to patients with significant pathologies.”

Dr. David Moffat, CTO, MPL, added: “I am very pleased to be taking the helm as CTO at MPL as we progress our lead asset into clinical trials and diversify and advance our preclinical pipeline to embrace additional drug targets and lead chemistries. The differentiated approach of our technology has the reach to address multiple indications where the immune system is dysregulated by aberrant macrophage activity, for potentially wide-ranging clinical benefit. As co-originator of the ESMTM technology I am proud of MPL’s achievements to date and look forward to working with our enhanced team in support of the further growth and development of Macrophage Pharma.”

Venkat brings over 15 years of experience in the biopharmaceutical industry most recently with Glenmark Pharmaceuticals where he was a senior vice president and global head of translational sciences leading the translational programmes of the Company’s innovative preclinical and clinical portfolio. He co-founded APC Therapeutics Inc., a small molecule immuno-oncology startup, the lead programme of which was licensed to Glenmark. Previously, Dr Reddy acted as a senior director of strategic partnerships at Pfizer’s Center for Therapeutic Innovation. Prior to that he held roles with Sanofi, as head of bio-innovation and as global head of oncology target discovery where he was involved in target identification and validation (TIDVAL) function and progression of multiple programmes from preclinical to clinical trials. Before joining Sanofi, Dr Reddy was a group leader in oncology drug discovery at the Novartis Institute for Functional Genomics, San Diego. He received his PhD in human biology at Ludwig Maximilians Universität, Munich and completed a post-doctoral fellowship in oncology and immunology at Scripps Research Institute, La Jolla.

Dr Moffat co-founded MPL in November 2014 and is co-inventor in the discovery and development of the ESMTM technology platform. Previously he has been director of chemistry at Chroma Therapeutics from 2004 to 2012, during which three molecules from his chemistry team were progressed to the clinic including the macrophage-targeted histone deacetylase inhibitors CHR-2845 and CHR-5154. He was also head of chemistry at Celltech from 2001 to 2004, prior to its acquisition by UCB, having begun his industrial career there in 1989. Dr Moffat has extensive experience in oncology and inflammation preclinical research and has led groups which have identified numerous clinical development candidates in these therapeutic areas. He holds BSc and PhD degrees from the University of Glasgow and is author and inventor on more than 70 patents and publications.

Macrophage Pharma at JP Morgan Healthcare Conference, San Francisco

Søren Bregenholt and Venkat Reddy will be at the 38th Annual J.P. Morgan Healthcare Conference on 13-16 January 2020 in San Francisco, California.

Søren Bregenholt will also be presenting at Biotech Showcase 2020 (13-15 January 2020) on Monday 13th January 2020 at 3pm in Franciscan B (Ballroom Level).

Please get in touch, details below, if you would like to set up a meeting.

ENDS

About Macrophage Pharma

Based on its proprietary Esterase Motif Technology™ (ESM™) platform, Macrophage Pharma is developing a novel and unique class of small molecule therapeutics which modulate immune responses though transcriptional reprogramming of monocytes and macrophages to combat disease. The Company’s novel ESM™ technology platform is designed to deliver small molecule drugs to macrophages in a highly selective manner. The Company is developing multiple programs inhibiting key pathways in macrophages in disease including the lead, a macrophage targeted p38 MAPK inhibitor programme.

The Company was founded by the CRT Pioneer Fund (CPF) and concluded a Series A financing in 2017 with CPF, Aglaia Oncology Funds, Novo Holdings A/S and M Ventures. Please visit the company website for further information: dev.macrophage.jacklogic.com

Contacts:

Macrophage Pharma Limited

Dr Søren Bregenholt, Chief Executive Officer,

Email: sb@macrophagepharma.com

Tel: +45 27284533

Optimum Strategic Communications

Hollie Vile, Mary Clark, Supriya Mathur

Email: hollie@optimumcomms.com

Tel: +44 (0) 203 714 1789

Categories
Our News

Macrophage Pharma Appoints Dr Anker Lundemose to the Board of Directors

Appointment widens industry leadership perspective, translational and commercial expertise

26 September 2019, Windsor, UK: Macrophage Pharma Limited (‘MPL’), a company focused on the discovery and development of next-generation immunomodulatory small molecules inducing transcriptional reprofiling of macrophages to combat cancer and other diseases, announced today that it has appointed Dr. Anker Lundemose as independent non-executive director.

Commenting on the appointment, Dr Michael Moore, Chairman of Macrophage Pharma, said: “On behalf of the Board I am pleased to welcome Anker as an independent director who has developed an outstanding reputation for having founded and built several successful companies within the European biotech sector.  As MPL evolves into the next stage of its development Anker will prove a valuable resource in the translation of the products of our proprietary Esterase Sensitive Motif™ (ESM™) platform and in the formulation of commercial strategies to bring our macrophage-directed small molecule drugs to cancer patients and those with other serious diseases.

Dr Anker Lundemose, said: “I am very happy to join Macrophage Pharma as an independent director, and I look forward to working closely with my new board colleagues and the CEO to take the Company to the next stage. The ESM™ platform with its pharmaceutical potential to achieve macrophage transcriptional reprogramming in several diseases, is impressive and differentiated from other immunomodulatory approaches.  With the current configuration of seasoned investors, CEO and executive team, the Company is well positioned to leverage that potential for the benefit of patients and all stakeholders.”

Anker Lundemose is a Danish national and currently Chief Executive Officer of Mission Therapeutics Ltd in Cambridge, UK. In a biopharma career spanning over twenty-five years, he brings extensive international experience in areas of management, business development, corporate development, R&D strategy & execution, and financing. Moreover, Anker has successfully built and exited several biotech companies and has cumulative experience in both public and private companies. Currently he is a director of Antag Therapeutics and Inthera Biosciences.  Anker has MD, PhD and DMSc degrees from the University of Aarhus, Denmark

ENDS         

About Macrophage Pharma

Based on its proprietary Esterase Motif Technology™ (ESM™) platform, Macrophage Pharma is developing a novel and unique class of small molecule therapeutics which modulate immune responses though transcriptional reprogramming of monocytes and macrophages to combat disease. The Company’s novel ESM™ technology platform is designed to deliver small molecule drugs to macrophages in a highly selective manner. The company is developing multiple programs inhibiting key pathways in macrophages in disease including the lead, a macrophage targeted p38MAP inhibitor programme for cancer.

The Company was founded by the CRT Pioneer Fund (CPF) and concluded a Series A financing in 2017 with CPF, Aglaia Oncology Funds, Novo Holdings A/S and M Ventures. Please visit the company website for further information: dev.macrophage.jacklogic.com

Contacts:

Macrophage Pharma Limited

Dr Soren Bregenholt, Chief Executive Officer,

Email: sb@macrophagepharma.com

Tel: +45 27284533

Optimum Strategic Communications

Hollie Vile, Mary Clark, Supriya Mathur

Email: hollie@optimumcomms.com

Tel: +44 (0) 203 950 9144